UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~December~~January 3031, ~~2010~~2011

US Oncology Holdings, Inc.
US Oncology, Inc.

(Exact name of registrant as specified in its charter)

Delaware	333-126922	90-0222104
Delaware	0-26190	84-1213501
(State or other jurisdiction of	(Commission File Number)	(I.R.S. Employer Identification No.)
incorporation)


Delaware Delaware (State or other jurisdiction of incorporation)		333-126922 0-26190 (Commission File Number)		90-0222104 84-1213501 (I.R.S. Employer Identification No.)

10101 Woodloch Forest Drive, The Woodlands, Texas		77380
(Address of principal executive offices)		(Zip Code)


10101 Woodloch Forest, The Woodlands, Texas (Address of principal executive offices)		77380 (Zip Code)

Registrant’s telephone number, including area code: (281) 863-1000

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 1.02		Termination of a Material Definitive Agreement.

AsOn ~~previously disclosed, on November~~January 131, ~~2010~~2011, US Oncology Holdings, Inc. (“Holdings”) ~~entered~~completed ~~into an~~its ~~Agreement~~previously ~~and~~disclosed redemption ~~Plan~~of all of ~~Merger~~its ~~(the~~outstanding ~~“Merger~~Senior ~~Agreement”)~~Unsecured byFloating ~~and~~Rate ~~among~~Toggle ~~McKesson Corporation~~Notes due 2012 (the “~~McKesson~~Floating Rate Notes”),. ~~Utah~~The ~~Acquisition~~Floating ~~Corporation,~~Rate aNotes ~~wholly~~were ~~owned~~redeemed ~~subsidiary~~for a total of ~~McKesson~~approximately $540 ~~(“Merger~~million, ~~Sub”)~~consisting of the principal amount, ~~Holdings~~together with the accrued and ~~Utah~~unpaid ~~Stockholders’~~interest ~~Agent~~thereon, thereby ~~LLC,~~terminating asand ~~Stockholders’~~discharging ~~Agent.~~all Inof ~~accordance with~~Holdings’ obligations under the ~~terms~~Floating ofRate Notes and the ~~Merger~~related ~~Agreement~~indenture, ondated ~~December~~as of March 3013, ~~2010~~2007, ~~Merger~~among ~~Sub~~Holdings, ~~merged~~the ~~with~~subsidiary ~~and~~guarantors ~~into~~party ~~Holdings~~thereto, and Wilmington Trust FSB (~~the~~as ~~“Merger”)~~successor ~~with~~to ~~Holdings~~LaSalle ~~continuing~~Bank asNational ~~the~~Association), ~~surviving~~as ~~corporation~~trustee.

OnThe ~~December 30,~~Floating ~~2010,~~Rate inNotes ~~connection~~were ~~with~~redeemed under the ~~consummation~~terms of the ~~Merger,~~previously ~~Holdings~~disclosed ~~and~~Agreement ~~its wholly~~and ~~owned~~Plan ~~subsidiary,~~of ~~US Oncology~~Merger, ~~Inc. (the “Company”), terminated its credit agreement,~~ dated as of ~~August~~ November 261, ~~2009~~2010, ~~among~~by ~~Holdings, the Company, Deutsche Bank Securities, Inc., J.P. Morgan Securities Inc., Morgan Stanley Senior Funding, Inc.,~~ and ~~Wells~~among ~~Fargo~~McKesson ~~Securities,~~Corporation ~~LLC~~(“McKesson”), ~~as the~~ ~~Lenders~~Holdings, ~~Deutsche~~Utah ~~Bank~~Acquisition ~~Trust Company Americas~~Corporation, asa ~~the~~wholly ~~Administrative~~owned ~~Agent~~subsidiary ~~and~~of ~~Collateral Agent~~McKesson, ~~Morgan~~ ~~Stanley Senior Funding, Inc.~~ and ~~Wells Fargo Bank, N.A., as the Syndication Agents, and~~Utah ~~JPMorgan~~Stockholders’ ~~Chase~~Agent ~~Bank~~LLC, ~~N.A.~~ as ~~the~~Stockholders’ ~~Documentation~~ Agent, ~~(the~~pursuant ~~“Credit~~to ~~Agreement”). The related guarantee and collateral agreements under~~ which Holdings, ~~the~~became ~~Company~~a ~~and~~direct ~~certain subsidiaries~~wholly ~~pledged~~owned ~~substantially~~subsidiary ~~all~~ of the tangible and intangible assets and properties of Holdings, the Company and such subsidiaries in favor of the Collateral Agent in order to guarantee payments under the Credit Agreement, were also terminatedMcKesson.

~~The~~Item ~~material terms and conditions of the Credit Agreement were previously described in a Current Report on Form~~ 8~~-K filed by Holdings and the Company with the Securities and Exchange Commission on August 28, 2009, and are incorporated herein by reference~~.01 AsOther ~~a condition to, and concurrently with, the consummation of the Merger, McKesson repaid all amounts outstanding under the Credit Agreement~~Events. ~~Neither Holdings nor the Company incurred any prepayment or early termination penalties in connection with termination of these agreements.~~

~~Item~~As previously announced, US Oncology, Inc. (the “Company”), the wholly owned subsidiary of Holdings, called for redemption all of its outstanding 9.125% Senior Secured Notes due 2017 (the “9.125% Notes”) and all of its outstanding 10.75% Senior Subordinated Notes due 2014 (the “10.75% Notes”), which is scheduled to occur on February 516, 2011 for the 9.01125% ~~Changes~~Notes and February 17, 2011 for the 10.75% Notes. In accordance with the terms of the indenture, the redemption of the 9.125% Notes is subject to a “make-whole” premium, which will be computed using a discount rate equal to a Treasury rate (which is equal to the yield to maturity of the United States Treasury security selected by an independent investment bank as having a maturity comparable to the remaining term of the 9.125% Notes, which are due August 15, 2017) plus 50 basis points. The actual redemption price for the 9.125% Notes, including the “make-whole” premium, will be determined shortly before their redemption. In accordance with the terms of the indenture, the redemption of the 10.75% Notes is subject to a specified redemption price, which, in ~~Control~~the case of any optional redemption prior to August 15, 2011, is equal to 103.583% of the ~~Registrant~~outstanding principal amount of 10.75% Notes. As disclosed in Financial Note 9 to the Unaudited Condensed Consolidated Financial Statements included in McKesson’s Form 10-Q for the fiscal quarter ended December 31, 2010, McKesson determined the fair value of the 9.125% Notes to be approximately $923 million, including the associated redemption premium which was computed using a United States Treasury security maturing in August 2017, and the fair value of the 10.75% Notes to be approximately $288 million.

On December 30, 2010, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Holdings with Holdings continuing as the surviving corporation. Prior to the Merger, a majority of the common stock of Holdings was held by Welsh, Carson, Anderson & Stowe IX, L.P. and its affiliates.

As a result of the Merger, Holdings became a direct wholly owned subsidiary of McKesson. In addition, shares of Holdings common stock issued and outstanding immediately prior to the Merger, other than shares held by (i) any stockholder who properly exercised appraisal rights in accordance with the Delaware General Corporation Law, (ii) Holdings as treasury stock, and (iii) Holdings, McKesson or any direct or indirect wholly owned subsidiary of Holdings or McKesson, were cancelled and automatically converted into the right to receive an aggregate amount of approximately $415 million in cash, without interest and less any applicable withholding taxes, subject to certain escrow obligations or adjustments.

The total transaction, including the assumption or repayment of the outstanding debt of Holdings and its subsidiaries, was valued at approximately $2.2 billion. The cash merger consideration paid by McKesson was approximately $415 million, and immediately prior to the Merger, Holdings called all of its outstanding Senior Unsecured Floating Rate Toggle Notes due 2012 (the “Floating Rate Notes”) for redemption, and the Company called all of its outstanding 9.125% Senior Secured Notes due 2017 (the “9.125% Notes”) and 10.75% Senior Subordinated Notes due 2014 (the “10.75% Notes,” and together with the Floating Rate Notes and the 9.125% Notes, the “Notes”) for redemption, which is expected to occur on January 31, 2011 for the Floating Rate Notes, February 16, 2011 for the 9.125% Notes and February 17, 2011 for the 10.75% Notes. The aggregate redemption payment for the Notes is estimated to be approximately $1.79 billion, including the principal amounts, accrued and unpaid interest and

associated redemption premiums. However, the exact amount of the redemption premium to be paid with respect to the 9.125% Notes will not be known until shortly before the redemption date for such Notes. The redemption of Notes by Holdings and the Company will be funded by McKesson from cash and, if necessary, borrowings by McKesson under its one-year unsecured senior bridge term loan agreement.

Upon consummation of the Merger, all officers and members of the Board of Directors of Holdings and the Company voluntarily resigned, and were replaced by the officers and directors designated by McKesson.

Item 5.05 Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics.

On December 30, 2010, as a result of the Merger, McKesson’s Code of Ethics, which can be found on McKesson’s web site, www.mckesson.com, under the Investors — Corporate Governance tab, became applicable to Holdings and the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, each of the registrants has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: ~~December~~February 304, ~~2010~~ 2011

US ~~Oncology~~ONCOLOGY ~~Holdings~~HOLDINGS, ~~Inc~~INC. and US ~~Oncology~~ONCOLOGY, ~~Inc~~INC. By: /s/ Willie C. Bogan Willie C. Bogan Vice President and Secretary

Filing Compare · US ONCOLOGY INC